Venus Remedies Ltd
Fri 18/07/2025,15:58:55 | NSE : VENUSREM
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 555.00
Previous Close
₹ 552.80
Volume
63656
Mkt Cap ( Rs. Cr)
₹738.66
High
₹ 567.80
Low
₹ 525.20
52 Week High
₹ 567.80
52 Week Low
₹ 270.25
Book Value Per Share
₹ 369.73
Dividend Yield
0.00
Face Value
₹ 10.00
What’s Your Call?
Collective community sentiment on Venus Remedies Ltd
Your Vote -
Buy
43.75%
Hold
18.75%
Sell
37.50%
43.75%
16 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
NaN%
Sell Order Quantity
NaN%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Option Chain
Analyzes market sentiment, predicts Venus Remedies Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Venus Remedies L has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2025
-
Venus Remedies L - Structural Digital Database
-
Venus Remedies L - Copy of Newspaper Publication
-
Venus Remedies L - Board Meeting Outcome for Outcome Of Board Meeting Dated 8Th July 2025.
-
Venus Remedies L - Outcome of Board Meeting
-
Venus Remedies L - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Venus Remedies L - Updates
-
Venus Remedies L - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Venus Remedies L - Board Meeting Intimation
-
Venus Remedies L - Board Meeting Intimation for Notice Of Board Meeting To Be Held On 8Th July 2025
-
Venus Remedies L - Trading Window
-
Venus Remedies L - Trading Window-XBRL
-
Venus Remedies L - Trading Window
-
Venus Remedies L - Disclosure under SEBI Takeover Regulations
-
Venus Remedies L - Copy of Newspaper Publication
-
Venus Remedies L - Copy of Newspaper Publication
-
Venus Remedies L Q4 net profit up 18.13% at Rs 14.79 cr
-
Venus Remedies L - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
-
Venus Remedies L - Announcement under Regulation 30 (LODR)-Change in Management
-
Venus Remedies L - Change in Management
-
Venus Remedies L - Outcome of Board Meeting
-
Venus Remedies L - Audited Financial Results As On 31.03.2025
-
Venus Remedies L - Outcome of Board Meeting
-
Venus Remedies L - Board Meeting Outcome for Outcome Of Board Meeting Dated 26.05.2025.
-
Venus Remedies L - Updates
-
Venus Remedies secures Ukrainian GMP Renewal, Boosting Global Pharmaceutical Expansion
-
Venus Remedies L - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Venus Remedies L - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
-
Venus Remedies secures Marketing Authorization in Philippines
-
Venus Remedies achieves major milestone with UNICEF
-
Venus Remedies gets new marketing nod for two drugs in Europe
-
Venus Remedies secures marketing authorisations for Docetaxel and Cytarabine
-
Venus Remedies Consumer Healthcare Division, R3SET forays into wellness segment
-
Venus Remedies receives market authorisations for Enoxaparin in Azerbaijan
-
Venus Remedies grant market authorisations in Saudi Arabia and Philippines
-
Venus Remedies arm gets authorization to market Cancer Drug in UK
-
Venus Remedies gets marketing nod for six chemotherapy drugs from Philippines
-
Venus Remedies extends its oncology portfolio in South Eastern Europe
-
Venus Remedies on expansion spree in Gulf
-
Venus Remedies oncology wing product registration go upto 506
-
Venus Remedies gets marketing nod for chemo drug.
-
Venus Remedies bags nod to market Meropenem, its block buster generic drug, in Spain
-
Venus Remedies gets Ukrainian GMP nod
-
Venus Remedies bags Saudi GMP nod for all its production facilities
-
Venus Remedies
-
Venus Remedies enters into partnership with West Pharmaceutical Service
Key fundamentals
Evaluate the intrinsic value of Venus Remedies Ltd stock
| Name | March-25 | March-24 | March-23 | March-22 | March-21 |
|---|---|---|---|---|---|
| Assets | 589.5 | 547.2703 | 516.7264 | 488.0923 | 447.7034 |
| Liabilities | 589.5 | 547.2703 | 516.7264 | 488.0923 | 447.7034 |
| Equity | 13.37 | 13.367 | 13.367 | 13.367 | 12.342 |
| Gross Profit | 69.99 | 60.8913 | 61.5258 | 68.8218 | 46.8627 |
| Net Profit | 52.55 | 30.5004 | 28.9644 | 48.9866 | 54.2724 |
| Cash From Operating Activities | 83.1 | 35.3826 | 28.0548 | 40.8998 | 132.6673 |
| NPM(%) | 8.21 | 5.3 | 5.38 | 8.51 | 10.54 |
| Revenue | 639.46 | 575.2124 | 537.6619 | 575.181 | 514.623 |
| Expenses | 569.47 | 514.3211 | 476.1361 | 506.3592 | 467.7603 |
| ROE(%) | 10.63 | 6.17 | 5.86 | 9.91 | 10.98 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|---|---|---|---|
| 3 | 30 | 0 | 279.5 | |
| 23 Sep 2013 | 3 | 30 | 0 | 304.45 |
| 20 Sep 2012 | 3 | 30 | 0 | 228.05 |
| 22 Sep 2011 | 3 | 30 | 0 | 253.15 |
| 23 Sep 2010 | 3 | 30 | 0 | 268 |
| 17 Sep 2009 | 3 | 30 | 0 | 278.45 |
| 12 Sep 2008 | 4 | 40 | 0 | 400.85 |
| 18 Sep 2007 | 3 | 30 | 0 | 470.05 |
Peers
Other companies within the same industry or sector that are comparable to Venus Remedies Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 933.30 | 0.89 | 30.97 | 314.55 | 301.39 | 0.54 |
| Lotus Eye Hospital and Institute Ltd | 75.41 | 1.51 | 215.46 | 1146.19 | 3.55 | 0.00 |
| Vaishali Pharma Ltd | 12.77 | -1.69 | 212.83 | 590.79 | 3.13 | 0.00 |
| Astec Lifesciences Ltd | 901.45 | -0.84 | 0.00 | 1080.88 | -601.21 | 0.00 |
Company Info
M/s VENUS REMEDIES LTD. was incorporated as a private limited company on 15th day of Sept. 1989 in the name and style of Venus Glucose Pvt Ltd, and subsequently converted into a public limited company, vide fresh certificate of incorporation dated 19th Sept. 1994 and the name was converted as "Venus Remedies Ltd" under the Companies Act, issued by the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh at Jalandhar. The company started its production in the year 1991 with Intravenous/Intramuscular (IV/IM) injectable forms at its running unit located at 52, Ind. Area. Phase-I, Panchkula Distt. Ambala (Haryana). Subsequently the company introduced Eye/Ear/Nasal Drops during the year 1994. During the same year, the company also expanded its existing capacity from 9 lacs pieces per annum to 15 lacs pieces per annum and that of 9 lacs pieces to 20 lacs pieces per annum of IV fluids section and vial section respectively. And, during 1994, the company has also certified as "WHO-GMP" (Good practices in manufacturing and quality control) as specified by WHO, Geneva by the State Drug Controller of Haryana. MAIN OBJECTS OF THE COMPANY The main objects of the company as set out in its Memorandum of Association are : 1. To manufacture, import, export of intravenous transfusion fluids and formations such as dextrose, dextrose with sodium chloride, normal saline, isolate P, isolate M, isolate G, isolate E, Mannitol etc. in various concentrations, intravenous solution for dialysis purposes, ACD Sterile bottles for blood collections, pharmaceutical parenteral preparations like Aminophylline, Adernaline, Water for injection, Chloroquine Sulphate, Sodium bi-carbonate, Analgin, Diazepam, Oxyphenbutazone & other injectables. 2. To carry on the business of deriving, formulating, purchasing, producing manufacturing, preparing, processing, mising, compounding, refining, marketing, distributing, selling and trading in pharmaceuticals, Chemicals, cosmetics, perfumes, medicines and drugs of all kinds, specifications and descriptions, and to do so especially in respect of all kinds of analgesics and antipyretics. 3. To carry on the business of purchasing, producing manufacturing, preparing, processing, mixing, compounding, refining, marketing, distributing, selling and trading in all classes and kinds of raw material ingredients, mixtures, compounds and derivatives connected to, intermediate in or associated with the manufacture production and sale of pharmaceuticals, chemicals medicines and drugs. 4. To carry on the business of vialling, bottling, packing. repacking and processing of capsules, syrups, tablets, injectables, aerosoles and ointment, bulk drugs and chemicals. 2005 -Venus Remedies successfully launches its Brand "Ronem" -Venus Remedies announces Strategic Marketing tie up with M/S Cadila Pharmaceuticals Ltd - M/s Themis Medicare Ltd enters into a Strategic Marketing Tie Up with Venus Remedies Ltd. -Delist equity shares from Delhi, Jaipur & Ahmedabad Stock Exchanges. -Venus Remedies has entered into Strategic Marketing Agreement with Merck Specialties Pvt Ltd, a wholly owned Subsidiary of Merck Ltd, Darmstadt, Germany, for its Oncology range of products. -Venus Remedies sets up a wholly owned subsidiary in Germany 2006 -Venus Remedies Ltd has informed that a Company has been granted three prestigious ISO certifications -Venus Remedies in-licenses product Technology from USA 2007 -Venus Remedies Ltd has signed an agreement with M/s. Pharma Match R&D B.V. a limited Company based at Amsterdam, Netherlands for jointly preparing, registering and marketing an EU E-CTD Dossier for a latest generation Carbapenem Injectible. 2008 -Venus facilities Accredited with European GMP Certification. -Venus Remedies Ltd has informed that the Company's manufacturing facilities have been approved by the G.F.T.O of Syria for manufacturing and exporting its products to Syria. -Venus Remedies - European AMP Accreditation for Venus Oncology Facilities. -Venus Remedies Ltd has informed that the Company has successfully launched its fourth Research Product, a Fixed Dose Combination of Cephalosporin with aminoglycoside under the Brand name "TOBRACEF" in Domestic Market for the first time globally. 2009 -Venus Remedies - Product Patent for "TOBRACEF" granted in South Africa. -Venus Bags Another Product Patent from South Africa for POTENTOX. --Registered Office of the Company has been shifted from SCO 39, Sector 26, Chandigarh. to SCO 857, C. No. 10, IInd Floor, NAC Manimajra, Chandigarh - 160 101. 2010 -Venus Remedies Ltd, a fast-growing pharmaceutical company in the country, has launched MEBATIC, a unique antibiotic combination in infusion form to cure severe gastro intestinal (GI) infections. -"Venus Remedies receives GMP Certification from Botswana". -Venus Remedies ties up with IMTECH and Panjab Univ to develop Typhoid detection kits. -The Company has received approval from the Reserve Bank of India for rollover of FCCB USD 5mn, with YTM @4% with maturity till February 15, 2015. -Venus Remedies research Blockbuster "Sulbactomax" gets European Union Patent". 2011 -"Venus Remedies Anti-Cancer drug "GEMCITABINE" gets UK MHRA approval". -"Sulbactomax" patent from Mexico strengthens Venus Remedies' presence in Latin America". -"Venus Remedies successfully completes Phase I & II Clinical Trials of TUMATREK (VRP162O), cancer detection molecule". -Venus Remedies Ltd wins Gold Medal for TROIS under DST - Lockheed Martin India Innovation Growth Program 2011. -"Venus launches its patented research product ACHNIL" in India". -"Venus Remedies wins "India Manufacturing Excellence Award 2011". 2012 -VenusRemedis - Venus's ACHNIL, BioSpectrum Product of the Year 2012. -VenusRemedis - Innovative Solution for alleviating cancer. -"Venus Remedies introduces "Ready-to-Use" Single Vial Taxedol in India". -Venus Remedies Limited introduced TROIS that is a research based, patent protected topical nano-emulsion product in India -The Company has won Manufacturing Award for its world class manufacturing and operational excellence at the "Industry 2.0 Manufacturing Innovation Conclave 2012". -"Venus wins Patent award in Silver Category". 2013 -"Venus Remedies launches Elores - CSE 1034, a US Patent projected product in India". -"Venus Remedies signs MoU for Elores with South African pharmaceutical firm". -"Venus Remedies takes its flagship product, Elores into Latin America". -"Venus launches its first OTC product Ezenus". -"Venus sign Exclusive Marketing Rights deal for its novel Antibiotic Ajuvant Entity to South Africas second largest Pharmaceutical Company - Adcock". -"Venus Remedies MEROPENEM receives market authorization in Mexico". -Venus Remedies Ltd has informed regarding "ELORES awarded Gold Medal for being the best Innovation of 2013" -"Venus wins Innovative 100 Award for ELORES". -"Venus bags UBM India Pharma Award for Elores". 2014 -"Venus ties up with Mylan for marketing meropenem in three European countries". - "VMRC Drug VRP008 to Fight "MULTI-DRUG Resistant Bacteria" Receives European Patent". -"Venus Receives Market Authorization for Meropenem from SWITZERLAND (SWISSMEDIC)". 2015 -"Venus announces issuance of Indian Patent for Vancoplus". -Venus Remedies holds blood, organ donation camps on its Panchkula premises. 2016 -"Venus launches its second OTC product "SWATCH GAURD" a herbal Hand Sanitizer". 2019 -"Venus announces deal with Cipla for its patented product Elores for Indian Territory". 2021 -Venus Remedies launched its full-fledged Consumer Healthcare Division. -Venus Remedies Limited has been selected for Production Linked Incentive Scheme (PLI) of the Government of India. 2022 -Venus Remedies won WHO Good Distribution Practices (GDP) certification for quality services across entire supply chain. -Venus remedies wins ambitionbox best places to work award. -Venus Remedies Limited has been Great Place to Work Certified. 2023-"Venus Earns Prestigious FICCI Healthcare Award 2023 for Pioneering 'Organ-on-a-Chip' Research Model".-"Venus Remedies Limited Honored with Best Working Conditions Award 2022".-Venus Remedies launched flagship R&D drug Elores in Oman.-Venus Remedies oncology wing product registrations go up to 506 with marketing approvals from four more countries.-"Venus Remedies Awarded Ukrainian GMP Approval for Its Carbapenem, Oncology Parenteral Facilities".-'Venus Remedies awarded Saudi GMP approval for all its production facilities in Baddi.'. 2023 -"Venus Earns Prestigious FICCI Healthcare Award 2023 for Pioneering 'Organ-on-a-Chip' Research Model". -"Venus Remedies Limited Honored with Best Working Conditions Award 2022". -Venus Remedies has launched its flagship R&D drug, Elores, in the USD 1.4-billion pharmaceutical market in Oman. -"Venus Remedies Awarded Ukrainian GMP Approval for Its Carbapenem, Oncology Parenteral Facilities.". -'Venus Remedies awarded Saudi GMP approval for all its production facilities in Baddi.'. 2024 -Venus Remedies achieves major milestone with UNICEF by securing the prestigious tender for its antibiotic product. -Venus Remedies awarded with Rs.2.50cr as the remaining part of its first incentive under PLi scheme. -Venus Remedies awarded its first incentive of Rs.7.50 crores under PLI scheme.
M/s VENUS REMEDIES LTD. was incorporated as a private limited company on 15th day of Sept. 1989 in the name and style of Venus Glucose Pvt Ltd, and subsequently converted into a public limited company, vide fresh certificate of incorporation dated 19th Sept. 1994 and the name was converted as "Venus Remedies Ltd" under the Companies Act, issued by the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh at Jalandhar. The company started its production in the year 1991 with Intravenous/Intramuscular (IV/IM) injectable forms at its running unit located at 52, Ind. Area. Phase-I, Panchkula Distt. Ambala (Haryana). Subsequently the company introduced Eye/Ear/Nasal Drops during the year 1994. During the same year, the company also expanded its existing capacity from 9 lacs pieces per annum to 15 lacs pieces per annum and that of 9 lacs pieces to 20 lacs pieces per annum of IV fluids section and vial section respectively. And, during 1994, the company has also certified as "WHO-GMP" (Good practices in manufacturing and quality control) as specified by WHO, Geneva by the State Drug Controller of Haryana. MAIN OBJECTS OF THE COMPANY The main objects of the company as set out in its Memorandum of Association are : 1. To manufacture, import, export of intravenous transfusion fluids and formations such as dextrose, dextrose with sodium chloride, normal saline, isolate P, isolate M, isolate G, isolate E, Mannitol etc. in various concentrations, intravenous solution for dialysis purposes, ACD Sterile bottles for blood collections, pharmaceutical parenteral preparations like Aminophylline, Adernaline, Water for injection, Chloroquine Sulphate, Sodium bi-carbonate, Analgin, Diazepam, Oxyphenbutazone & other injectables. 2. To carry on the business of deriving, formulating, purchasing, producing manufacturing, preparing, processing, mising, compounding, refining, marketing, distributing, selling and trading in pharmaceuticals, Chemicals, cosmetics, perfumes, medicines and drugs of all kinds, specifications and descriptions, and to do so especially in respect of all kinds of analgesics and antipyretics. 3. To carry on the business of purchasing, producing manufacturing, preparing, processing, mixing, compounding, refining, marketing, distributing, selling and trading in all classes and kinds of raw material ingredients, mixtures, compounds and derivatives connected to, intermediate in or associated with the manufacture production and sale of pharmaceuticals, chemicals medicines and drugs. 4. To carry on the business of vialling, bottling, packing. repacking and processing of capsules, syrups, tablets, injectables, aerosoles and ointment, bulk drugs and chemicals. 2005 -Venus Remedies successfully launches its Brand "Ronem" -Venus Remedies announces Strategic Marketing tie up with M/S Cadila Pharmaceuticals Ltd - M/s Themis Medicare Ltd enters into a Strategic Marketing Tie Up with Venus Remedies Ltd. -Delist equity shares from Delhi, Jaipur & Ahmedabad Stock Exchanges. -Venus Remedies has entered into Strategic Marketing Agreement with Merck Specialties Pvt Ltd, a wholly owned Subsidiary of Merck Ltd, Darmstadt, Germany, for its Oncology range of products. -Venus Remedies sets up a wholly owned subsidiary in Germany 2006 -Venus Remedies Ltd has informed that a Company has been granted three prestigious ISO certifications -Venus Remedies in-licenses product Technology from USA 2007 -Venus Remedies Ltd has signed an agreement with M/s. Pharma Match R&D B.V. a limited Company based at Amsterdam, Netherlands for jointly preparing, registering and marketing an EU E-CTD Dossier for a latest generation Carbapenem Injectible. 2008 -Venus facilities Accredited with European GMP Certification. -Venus Remedies Ltd has informed that the Company's manufacturing facilities have been approved by the G.F.T.O of Syria for manufacturing and exporting its products to Syria. -Venus Remedies - European AMP Accreditation for Venus Oncology Facilities. -Venus Remedies Ltd has informed that the Company has successfully launched its fourth Research Product, a Fixed Dose Combination of Cephalosporin with aminoglycoside under the Brand name "TOBRACEF" in Domestic Market for the first time globally. 2009 -Venus Remedies - Product Patent for "TOBRACEF" granted in South Africa. -Venus Bags Another Product Patent from South Africa for POTENTOX. --Registered Office of the Company has been shifted from SCO 39, Sector 26, Chandigarh. to SCO 857, C. No. 10, IInd Floor, NAC Manimajra, Chandigarh - 160 101. 2010 -Venus Remedies Ltd, a fast-growing pharmaceutical company in the country, has launched MEBATIC, a unique antibiotic combination in infusion form to cure severe gastro intestinal (GI) infections. -"Venus Remedies receives GMP Certification from Botswana". -Venus Remedies ties up with IMTECH and Panjab Univ to develop Typhoid detection kits. -The Company has received approval from the Reserve Bank of India for rollover of FCCB USD 5mn, with YTM @4% with maturity till February 15, 2015. -Venus Remedies research Blockbuster "Sulbactomax" gets European Union Patent". 2011 -"Venus Remedies Anti-Cancer drug "GEMCITABINE" gets UK MHRA approval". -"Sulbactomax" patent from Mexico strengthens Venus Remedies' presence in Latin America". -"Venus Remedies successfully completes Phase I & II Clinical Trials of TUMATREK (VRP162O), cancer detection molecule". -Venus Remedies Ltd wins Gold Medal for TROIS under DST - Lockheed Martin India Innovation Growth Program 2011. -"Venus launches its patented research product ACHNIL" in India". -"Venus Remedies wins "India Manufacturing Excellence Award 2011". 2012 -VenusRemedis - Venus's ACHNIL, BioSpectrum Product of the Year 2012. -VenusRemedis - Innovative Solution for alleviating cancer. -"Venus Remedies introduces "Ready-to-Use" Single Vial Taxedol in India". -Venus Remedies Limited introduced TROIS that is a research based, patent protected topical nano-emulsion product in India -The Company has won Manufacturing Award for its world class manufacturing and operational excellence at the "Industry 2.0 Manufacturing Innovation Conclave 2012". -"Venus wins Patent award in Silver Category". 2013 -"Venus Remedies launches Elores - CSE 1034, a US Patent projected product in India". -"Venus Remedies signs MoU for Elores with South African pharmaceutical firm". -"Venus Remedies takes its flagship product, Elores into Latin America". -"Venus launches its first OTC product Ezenus". -"Venus sign Exclusive Marketing Rights deal for its novel Antibiotic Ajuvant Entity to South Africas second largest Pharmaceutical Company - Adcock". -"Venus Remedies MEROPENEM receives market authorization in Mexico". -Venus Remedies Ltd has informed regarding "ELORES awarded Gold Medal for being the best Innovation of 2013" -"Venus wins Innovative 100 Award for ELORES". -"Venus bags UBM India Pharma Award for Elores". 2014 -"Venus ties up with Mylan for marketing meropenem in three European countries". - "VMRC Drug VRP008 to Fight "MULTI-DRUG Resistant Bacteria" Receives European Patent". -"Venus Receives Market Authorization for Meropenem from SWITZERLAND (SWISSMEDIC)". 2015 -"Venus announces issuance of Indian Patent for Vancoplus". -Venus Remedies holds blood, organ donation camps on its Panchkula premises. 2016 -"Venus launches its second OTC product "SWATCH GAURD" a herbal Hand Sanitizer". 2019 -"Venus announces deal with Cipla for its patented product Elores for Indian Territory". 2021 -Venus Remedies launched its full-fledged Consumer Healthcare Division. -Venus Remedies Limited has been selected for Production Linked Incentive Scheme (PLI) of the Government of India. 2022 -Venus Remedies won WHO Good Distribution Practices (GDP) certification for quality services across entire supply chain. -Venus remedies wins ambitionbox best places to work award. -Venus Remedies Limited has been Great Place to Work Certified. 2023-"Venus Earns Prestigious FICCI Healthcare Award 2023 for Pioneering 'Organ-on-a-Chip' Research Model".-"Venus Remedies Limited Honored with Best Working Conditions Award 2022".-Venus Remedies launched flagship R&D drug Elores in Oman.-Venus Remedies oncology wing product registrations go up to 506 with marketing approvals from four more countries.-"Venus Remedies Awarded Ukrainian GMP Approval for Its Carbapenem, Oncology Parenteral Facilities".-'Venus Remedies awarded Saudi GMP approval for all its production facilities in Baddi.'. 2023 -"Venus Earns Prestigious FICCI Healthcare Award 2023 for Pioneering 'Organ-on-a-Chip' Research Model". -"Venus Remedies Limited Honored with Best Working Conditions Award 2022". -Venus Remedies has launched its flagship R&D drug, Elores, in the USD 1.4-billion pharmaceutical market in Oman. -"Venus Remedies Awarded Ukrainian GMP Approval for Its Carbapenem, Oncology Parenteral Facilities.". -'Venus Remedies awarded Saudi GMP approval for all its production facilities in Baddi.'. 2024 -Venus Remedies achieves major milestone with UNICEF by securing the prestigious tender for its antibiotic product. -Venus Remedies awarded with Rs.2.50cr as the remaining part of its first incentive under PLi scheme. -Venus Remedies awarded its first incentive of Rs.7.50 crores under PLI scheme.
Read More
Parent Organisation
Venus Remedies Ltd.
Founded
15/09/1989
Managing Director
Mr.Pawan Chaudhary
NSE Symbol
VENUSREMBE
FAQ
The current price of Venus Remedies Ltd is ₹ 552.60.
The 52-week high for Venus Remedies Ltd is ₹ 567.80 and the 52-week low is ₹ 525.20.
The market capitalization of Venus Remedies Ltd is currently ₹ 738.66. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Venus Remedies Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Venus Remedies Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Venus Remedies Ltd shares.
The CEO of Venus Remedies Ltd is Mr.Pawan Chaudhary, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
